Protocol Page


	Study ID (Protocol Number)
	CA184-156


	STUDY LOCATIONS*
	Ashland Bellefonte Cancer Center Ashland, KY 41101 Recruiting	Cancer Care Of North Florida, Pa Lake City, FL 32024 Recruiting
	Cancer Care Associates Tulsa, OK 74104 Recruiting	Cancer Center Of Kansas Wichita, KS 67214 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
	STUDY OVERVIEW
	The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.